Cargando…
Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity
Proteasome inhibitors have distinct properties and the biochemical consequences of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viabi...
Autores principales: | McHugh, Angela, Fernandes, Kenneth, South, Andrew P., Mellerio, Jemima E., Salas-Alanís, Julio C., Proby, Charlotte M., Leigh, Irene M., Saville, Mark K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945540/ https://www.ncbi.nlm.nih.gov/pubmed/29755650 http://dx.doi.org/10.18632/oncotarget.24750 |
Ejemplares similares
-
Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity
por: Hepburn, Lydia A., et al.
Publicado: (2018) -
The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma
por: McHugh, Angela, et al.
Publicado: (2020) -
NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis
por: South, Andrew P, et al.
Publicado: (2014) -
The Ubiquitin Conjugating Enzyme: An Important Ubiquitin Transfer Platform in Ubiquitin-Proteasome System
por: Liu, Weigang, et al.
Publicado: (2020) -
A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing
por: Hassan, Sakinah, et al.
Publicado: (2019)